化学
癌症研究
细胞凋亡
喹唑啉
脱甲基酶
表观遗传学
食管癌
诱导剂
癌症
甲氧雌二醇
癌细胞
结构-活动关系
IC50型
信号转导
程序性细胞死亡
药理学
激酶
体外
铅化合物
肿瘤进展
作者
Li-Juan Zhao,Rui Yu,Ying Liu,Jia-Yi Yin,Hang Jin,Jingang Zhang,Cong-Jun Liu,Guo‐Liang Lu,Yan Li,Ning Wang,Yi‐Chao Zheng,Ya Gao,Kangdong Liu,Xing‐Jie Dai
标识
DOI:10.1021/acs.jmedchem.6c01218
摘要
Lysine-specific demethylase 1 (KDM1A) is an FAD-dependent epigenetic target implicated in cancer progression. Starting from lead compound ZY-1 (IC50 = 105 nM), we designed a series of quinazoline-based reversible KDM1A inhibitors via a functional group migration strategy. Structure-activity relationship studies (SARs) identified JH-1 as the most potent analogue, with an IC50 of 35 nM. JH-1 selectively binds KDM1A, inhibits H3K4me1/2 demethylation, and induces both ferroptosis (lipid ROS accumulation) and apoptosis in esophageal cancer cells. In a KYSE510 xenograft model, oral administration of JH-1 significantly suppressed tumor growth without obvious toxicity. These results establish JH-1 as a promising reversible KDM1A inhibitor and validate the quinazoline scaffold for epigenetic cancer therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI